Drugs / 3-OHB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03073356 | Mar → Nov 2017 | systolic heart failure | University of Aarhus | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02357550 | Mar 2015 → Jan 2016 | disorder of fatty acid and ketone body metabolism | University of Aarhus | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3-OHB | “3-OHB is infused intravenously.” NCT02357550 ↗ |
| Known as | 3-hydroxybutyrate | “3-hydroxybutyrate (OHB) infusion and b) saline infusion.” PMID 33074729 ↗ Oct 2020 |
| Known as | OHB | “3-hydroxybutyrate (OHB) infusion and b) saline infusion.” PMID 33074729 ↗ Oct 2020 |
| Route | Intravenous | “3-OHB is infused intravenously.” NCT02357550 ↗ |